相关实验视频

Updated: Jun 13, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

预测宫癌化学放射治疗生存率的PET:研究仍在继续

Matheus Henrique Leite E Silva¹, Matheus Aleixo Barbosa da Silva¹, Daniel Simões Reis Dos Santos¹

¹Faculty of Medicine.

Nuclear medicine communications

|June 5, 2025

概括

18F-氧葡萄糖PET/CT成像得分,特别是SUV 2SD和SUV per,结合BMI变化,可以预测宫癌患者的生存率. 这些基于PET的非侵入性成像指标有助于个性化治疗局部晚期疾病的治疗策略.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

宫癌仍然是一个重大的全球健康挑战.
个性化医疗需要非侵入性的方法来分层患者.
18F-氧葡萄糖PET/计算机断层扫描 (FDG-PET/CT) 对于宫癌的分期至关重要.

研究的目的:

通过基于PET的成像得分来确定宫癌患者的预测因素.
探索PET成像指标,BMI变化和患者存活率之间的关联.
评估非侵入性PET成像在个性化治疗决策中的潜力.

主要方法:

一项观察性研究涉及IIB-IIIB阶段的宫癌患者,这些患者接受了erlotinib和标准治疗.
使用卡普兰-梅尔和考克斯比例危险模型进行生存分析.
在治疗前和治疗后测量最大和平均PET参数 (SUV 2SD,SUV per,SUV max);BMI变化也被记录.

主要成果:

宫癌IIB期与比IIIB期更长的生存时间有关.
较低的SUV 2SD (<4.1) 或SUV per (<7.6) 与更大的BMI降低相结合,预测了更差的整体和无进展生存率 (P <0.05).
综合预处理的SUV指标 (SUVmax,SUVper,SUV2SD) 显示了显著生存分层的趋势 (P=0.057).

结论:

SUV 2SD和SUV per,以及BMI变化,与宫癌的生存预测有关.
佩特成像具有针对本地晚期子宫癌的个性化治疗决策的潜力.
基于PET的非侵入性评分可以在不增加成本的情况下增强个性化管理策略.

关键词:

18F 18F 18F 18F 18F 18F 18F 18F 18F 18F 18F 18F 18F 18F 这就是为什么CTCTCTCTCTCT 德国联邦财政总局PET 生存分析,生存分析.子宫瘤是什么子宫瘤

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...